 This study examined the effect of streptozotacin, STZ, an anti-cancer drug commonly used to treat neuroendocrine tumor, NET, patients on kidney cells. It was found that STZ causes cell death in kidney cells, but does not affect pancreatic beta cells. This suggests that STZ may be more effective at treating NETs than other cancer drugs, since it can target specific cells without damaging healthy ones. Additionally, this study identified the mechanism behind STZ's ability to cause kidney cell death, which involves DNA damage and subsequent P53 signaling. This finding could lead to new treatments for NET patients who are being treated with STZ. This article was authored by Kunihiro Nokai, Minato Yumura, at Sushi Minamida, and others.